Sandoz SPC challenge unsuccessful at English High Court

The English High Court has concluded that a supplementary protection certificate (SPC) challenged by Sandoz is valid, dismissing the dispute.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

In-house counsel

‘Companies that don’t leverage AI will struggle to keep up’, warns Umicore IP chief

26 October 2026 Umicore’s Sean Alexander has seen the profession change considerably over three decades, but some of its biggest changes may still lie ahead. He tells LSIPR why AI is prompting difficult decisions, what he is no longer willing to pay external counsel for and why Europe is the place to watch.

Biotech

10x and Parse set to end sequencing feud after appeals court defeat

23 October 2026 Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.

Pharma

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

22 October 2026 Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.

More features

‘Companies that don’t leverage AI will struggle to keep up’, warns Umicore IP chief

10x and Parse set to end sequencing feud after appeals court defeat

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

Amarin and Hikma call time on six-year skinny label fight

WATCH: Medmix global IP head on building business-focused IP teams

Fish & Richardson hires duo with ‘sophisticated’ tech patent expertise

Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

Sandoz SPC challenge unsuccessful at English High Court

More on this story

Editor's picks

Editor's picks

More features